Trends & Viral Yonhap News Culture · 2026-11-13

Move Over Injections: Oral Weight-Loss Pills Eye South Korea Launch Next Year After Milestone China Approval

Key Points
  • Eli Lilly's daily oral GLP-1 obesity medication, orforglipron, gained approval from China's National Medical Products Administration following clearance in the U.S., UAE, and UK.
  • In South Korea, where injectable options like Wegovy and Mounjaro sparked massive interest, both Eli Lilly and Novo Nordisk have applied for domestic approval for their oral pill formulations.
  • Industry insiders forecast that needle-free weight-loss pills could hit the South Korean market as early as next year as local Phase 3 trials advance.
Summary The global weight-loss drug craze is entering a major new chapter as pharmaceutical giants shift their focus from weekly injections to daily oral pills, with South Korea preparing for a landmark market launch as early as next year. According to industry reports and the Korea Biotechnology Industry Organization (KoreaBIO), Eli Lilly's oral GLP-1 weight-loss treatment orforglipron—known commercially in the United States as 'Poundayo' and branded as 'Muyuda' in China—was officially approved by China's National Medical Products Administration (NMPA) for adult weight management. Orforglipron, a compound originally licensed by Eli Lilly from Japan's Chugai Pharmaceutical, completed global Phase 3 clinical trials for obesity and type 2 diabetes. Its clearance in China marks the country's first approved oral GLP-1 receptor agonist, further expanding Eli Lilly's regulatory footprint following previous approvals in the United States, the United Arab Emirates, and the United Kingdom. This shift toward oral treatments comes at a time of immense public interest in South Korea. Dubbed 'miracle diet drugs' by local media and consumers, injectable GLP-1 therapies such as Eli Lilly's Mounjaro, Novo Nordisk's Wegovy, and Hanmi Pharmaceutical's domestically developed Efpeglenatide ('Efe') have dominated headlines and clinics. However, despite their proven efficacy, all current market offerings require weekly self-administered subcutaneous injections. The introduction of needle-free oral pills is widely expected to lower psychological barriers and improve patient adherence, fueling intense competition between multinational pharmaceutical companies. A high-stakes race is already underway in South Korea. Both Novo Nordisk and Eli Lilly have submitted applications to South Korea's Ministry of Food and Drug Safety (MFDS) for approval of their oral candidates—Wegovy Pill and Poundayo, respectively. Eli Lilly Korea is also conducting local Phase 3 clinical trials to evaluate Poundayo's efficacy and safety specifically in overweight individuals. Industry observers anticipate that the first oral anti-obesity medications could arrive in Korean clinics and pharmacies within the coming year, heralding a new era for medical weight management in the country.
Sponsored · Ad